To study the effects of nutritional supplementation of extremely active resveratrol (XAR) in healthy human individuals.
Not Applicable
- Registration Number
- CTRI/2017/09/009694
- Lead Sponsor
- Epigeneres Biotech Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Healthy volunteers of age 20 to 55 years of either sex who are not involved in any regular medication or supplementation.
2. Subjects having HDL level, normal, lower and less than lower range at screening visit.
3. Subjects who are willing to give their written informed consent and comply with the protocol requirements.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the efficacy of XAR Capsule 500mg (containing 10.5 mg of extremely active resveratrol) on HDL, DHEA and insulin level.Timepoint: 30 days
- Secondary Outcome Measures
Name Time Method To determine the efficacy of XAR Capsule on Total cholesterol, Very Low Density Lipoprotein, <br/ ><br>Low density lipoprotein, Triglyceride, Testosterone, Thrombotic, renal profile, Homocysteine, Estradiol and Anti-Mullerian Hormone. The effect of XAR will be analyzed on the expression of stem cell genes and other genes in the peripheral blood cells.Timepoint: 30 days